Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale

Research published in The Journal of Clinical Psychiatry characterizes patient-reported improvement with INGREZZA® (valbenazine) capsules across the KINECT® clinical program Publication establishes a clinically meaningful improvement threshold for the Tardive Dyskinesia Impact Scale (TDIS™) SAN DIEGO, April 29, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in The Journal of Clinical Psychiatry demonstrating how the Tardive Dyskinesia Impact Scale helps characterize patient-reported burden in tardive dyskinesia and has been used in clinical studies to assess meaningful improvement over the course of treatment with INGREZZA® (valbenazine) capsules. The article builds on the original validation of the Tardive Dyskinesia Impact Scale (TDIS™) by defining what meaningful improvement means and how TDIS results should be interpreted in clinical trials.